ENOCHIAN BIOSCI. DL-0001
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors… Read more
Market Cap & Net Worth: ENOCHIAN BIOSCI. DL-0001 (2Q5)
ENOCHIAN BIOSCI. DL-0001 (F:2Q5) has a market capitalization of $2.45 Million (€2.38 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #35931 globally and #4333 in its home market, demonstrating a 13.72% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ENOCHIAN BIOSCI. DL-0001's stock price €0.10 by its total outstanding shares 23180247 (23.18 Million).
ENOCHIAN BIOSCI. DL-0001 Market Cap History: 2022 to 2025
ENOCHIAN BIOSCI. DL-0001's market capitalization history from 2022 to 2025. Data shows change from $20.51 Million to $2.45 Million (-63.33% CAGR).
ENOCHIAN BIOSCI. DL-0001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ENOCHIAN BIOSCI. DL-0001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 2Q5 by Market Capitalization
Companies near ENOCHIAN BIOSCI. DL-0001 in the global market cap rankings as of March 19, 2026.
Key companies related to ENOCHIAN BIOSCI. DL-0001 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
ENOCHIAN BIOSCI. DL-0001 Historical Marketcap From 2022 to 2025
Between 2022 and today, ENOCHIAN BIOSCI. DL-0001's market cap moved from $20.51 Million to $ 2.45 Million, with a yearly change of -63.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €2.45 Million | -87.73% |
| 2024 | €19.94 Million | -70.70% |
| 2023 | €68.05 Million | +231.79% |
| 2022 | €20.51 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of ENOCHIAN BIOSCI. DL-0001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.45 Million USD |
| MoneyControl | $2.45 Million USD |
| MarketWatch | $2.45 Million USD |
| marketcap.company | $2.45 Million USD |
| Reuters | $2.45 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.